Agile Therapeutics to Present at Women’s Health 2016: The 24th Annual Congress
15 4월 2016 - 9:00PM
Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty
pharmaceutical company focused on the development and
commercialization of new prescription contraceptive products
announced today that Dr. Elizabeth Garner, Chief Medical Officer
will present on the topic of subject recruitment for the SECURE
Phase 3 Study at Women’s Health 2016: The 24th Annual Congress in
Washington, DC on April 17, 2016.
The poster presentation, titled “Social Media and
Text Messaging Outreach in the Recruitment of Millennials into a
Phase 3 Contraceptive Patch Study” will discuss the impact of the
use of social media to recruit young women to participate in the
SECURE Study, a Phase 3 trial of the investigational contraceptive
patch, Twirla®.
The SECURE Study is a multicenter, single-arm,
open-label Phase 3 clinical trial in which healthy women eighteen
and over will receive treatment with the investigational patch for
up to one year. The clinical trial will assess the effectiveness of
the patch in preventing pregnancy using the Pearl Index as the
primary contraceptive efficacy measure. Safety and tolerability
will also be evaluated. Twirla contains the active ingredients
ethinyl estradiol and levonorgestrel, both of which have an
established history of efficacy and safety in currently marketed
low-dose combination oral contraceptives. The patch is applied once
weekly for three weeks followed by a patch-free week, and is
designed to promote user compliance.
For more information, please visit
http://www.academyofwomenshealth.org.
About Agile
Agile Therapeutics is a women’s health specialty
pharmaceutical company focused on the development and
commercialization of new prescription contraceptive products. Our
product candidates are designed to provide women with contraceptive
options that offer greater convenience and facilitate compliance.
Our lead product candidate Twirla® (ethinyl estradiol and
levonorgestrel transdermal system), also known as AG200-15, is a
once-weekly prescription contraceptive patch currently in Phase 3
clinical development. Twirla is based on our proprietary
transdermal patch technology called Skinfusion®, which is designed
to provide advantages over currently available patches and is
intended to optimize patch adherence and patient
acceptability. For more information, please visit the company
website at www.agiletherapeutics.com.
Contact: Mary Coleman 609-683-1880
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024